Cytek Biosciences Business Summary

Cytek Biosciences, Inc. (CTKB) operates a specialized life sciences tools model, generating revenue through the sale of spectral flow cytometry instruments, proprietary reagents, and high-margin service contracts. The company’s business is divided into Product and Service segments, with a strategic focus on expanding recurring revenue, which reached 34% of its $201.5 million total revenue in 2025 following a 21% year-over-year growth in that category. Utilizing its patented Full Spectrum Profiling (FSP) technology, Cytek provides high-parameter cell analysis via its Aurora, Northern Lights, and Aurora Evo platforms, targeting a 2026 revenue guidance of $205 million to $212 million. Cytek competes directly with Becton, Dickinson and Company (BD), Thermo Fisher Scientific, and Agilent Technologies. Within this landscape, Cytek is positioned as a high-growth disruptor, leveraging superior spectral resolution and an installed base of 3,664 units to capture market share from legacy monochromatic incumbents while expanding its clinical and APAC footprints. The company was co-founded by CEO Dr. Wenbin Jiang and CTO Dr. Ming Yan, both of whom bring significant technical pedigree; Dr. Jiang co-founded E2O Communications (acquired by JDSU) and holds over 100 patents, while Dr. Yan’s background includes R&D leadership at AT&T Bell Laboratories and BD Biosciences. The executive team is rounded out by CFO William McCombe and Chief Legal Officer Valerie Barnett, managing a global operation that placed 630 instruments in 2025 alone. Cytek’s board includes industry veterans such as Vera Imper (ex-Roche/BD) and Richard Chin, with major institutional backing from RA Capital Management, Hillhouse Capital, and F-Prime Capital. This leadership structure, supported by a $261.5 million cash reserve as of year-end 2025, is focused on transitioning the company toward GAAP profitability through product innovation and the scaling of its Cytek Cloud ecosystem.